# A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

> **NCT06019559** · PHASE2 · COMPLETED · sponsor: **Kallyope Inc.** · enrollment: 155 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** K-757 120 mg BID and K-833 100 mg BID
- **DRUG:** K-757 120 mg BID and matching placebo to K-833
- **DRUG:** Matching placebo to K-757 and matching placebo to K-833

## Key facts

- **NCT ID:** NCT06019559
- **Lead sponsor:** Kallyope Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-15
- **Primary completion:** 2024-02-07
- **Final completion:** 2024-02-19
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2025-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06019559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06019559, "A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06019559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*